You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Lead Compound Discovery from Engineered Analogs of Occidiofungin
SBC: Sano Chemicals, Inc. Topic: NIAIDProject Summary Occidiofungin is a cyclic nonribosomally synthesized antifungal peptide with submicromolar fungicidal activity against a broad spectrum of fungi Occidiofungin is produced by the Gram negative bacterium Burkholderia contaminans From our structural characterization studies occidiofungin was determined to have a unique chemical composition Our studies have also revealed that occi ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Aminooxyacetic Acid Prodrugs for Colon Cancer Therapy
SBC: CBS THERAPEUTICS, INC. Topic: 102ABSTRACT Recent studies of the applicants support the role of the endogenous gaseous biological mediator hydrogen sulfide H S in colorectal cancer In specific the selective upregulation of cystathionine synthase CBS and the subsequent production of H S in colonic cancer cells serves as a pro survival factor by stimulating tumor cell bioenergetics ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Microparticulate mucosal vaccine for triple-negative breast cancer
SBC: KIROMIC BIOPHARMA INC Topic: 103ABSTRACT Triple negative breast cancerTNBCis a molecular subtype of breast cancer that is negative for expression of estrogen and progesterone receptors and human epidermal growth factor receptorHERClinicallyit is characterized by aggressive behaviordistinct patterns of metastasisand high rates of recurrence and mortalitySince TNBC tumor cells lack the necessary receptorsthe disease does not respo ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Aspirin-PC for Chemoprevention of Colorectal Cancer
SBC: PLx Opco Inc. Topic: NCIABSTRACT Colorectal cancerCRCis the third leading cause of cancer related deaths in the U SBased on numerous epidemiological studies and recent prospective clinical trialsthe use of daily aspirin is associated with a significant reduction in CRC incidencedeaths and metastatic spreadHoweverthe chronic use of this drug is limited due to the side effects of gastrointestinal bleeding ulceration in sus ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Oral Small Molecule STAT Inhibitor to Treat Cachexia in Chronic Kidney Disease
SBC: StemMed, Ltd. Topic: 400DESCRIPTION provided by applicant Chronic kidney disease CKD is a major public health problem in the US with an estimated prevalence of million patients enter hemodialysis or peritoneal dialysis programs yearly A serious complication in of patients with CKD is cachexia or muscle wasting which decreases quality of life and increases morbidity and mortality Unfortunately ...
STTR Phase II 2017 Department of Health and Human ServicesNational Institutes of Health -
Targeting Synaptotagmin to Prevent Airway Mucus Obstruction
SBC: Exotect, LLC Topic: NHLBIPROJECT SUMMARY Mucus dysfunction underlies the pathophysiology of a number of common respiratory diseases including asthma cystic fibrosis and chronic obstructive pulmonary disease COPD Asthma alone impacts of the US population resulting in considerable cost morbidity and occasional mortality caused by mucus hypersecretion Recently it was discovered that Synaptotagmin Syt regul ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Polo box PLK Inhibitors Target Tumors Resistant to ATP Competitive Compounds
SBC: PPI PHARMACEUTICALS, LLC Topic: NCIPolo like kinase PLK is a central player in regulating entry into and progression through mitosis Many studies have validated PLK as an anti tumor drug target and its inhibition is potently anti proliferative to cancer cells However recent data suggests that there are two major disadvantages of the conventional approach to blocking the kinase activity of PLK First both general kinome ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
Investigation of antibody drug conjugates of a novel target
SBC: WNTRIX INC Topic: NCIPROJECT SUMMARY Antibody drug conjugates ADCs are monoclonal antibodies mAbs that are covalently linked to cell killing drugs and have emerged as a major modality in anti cancer treatment This approach combines high specificity of mAbs against their antigen targets with highly potent cytotoxic drugs resulting in armed mAbs that deliver the payload drug to tumor cells with enriched levels ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Cloud based Application for the Joint Analysis of Multiple Big Data Types
SBC: MathNimbus Inc Topic: 400Project Summary Technology advances now enable the cost effective acquisition of Kandgt distinct data types from a common set of N bio samples where i the kth data type is represented by a data matrix with columns containing Pk measurements in N samples for k K and ii at least one of the data types is big i e Pk is much bigger than N for some k The rapid accumulation of such mult ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health -
A Novel Scaffold to Promote Skin Regeneration
SBC: FirstString Research, Inc Topic: NIAMSPROJECT SUMMARY Dermal scarring affects more than million people worldwide annually over million people are injured in motor vehicle accidents over million patients are severely burned and thousands of warriors are wounded in military blasts In severe burns more than of patients develop hypertrophic scar contraction which leads to hypertrophic scar contractures HSc HSc a ...
STTR Phase I 2017 Department of Health and Human ServicesNational Institutes of Health